[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606020":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":39,"collaborators":42,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":78,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Başakşehir Çam & Sakura City Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GON Block Group","EXPERIMENTAL",null,[13],"Procedure: Greater Occipital Nerve (GON) Blockade",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"PROCEDURE","Greater Occipital Nerve (GON) Blockade","The greater occipital nerve block (GONB) will be performed using anatomical landmarks (distal approach). The injection point is located at the medial one-third of the line between the external occipital protuberance and the mastoid process. A 26-gauge insulin needle will be used for the procedure. The block will be administered bilaterally with 0.5% bupivacaine, 1.5 ml per side (total 3 ml). The intervention will be repeated once weekly for a total of four sessions",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Tuba Tanyel Saraçoğlu","CONTACT","+90 212 909 60 00","tuba.saracoglu1@saglik.gov.tr",[27],{"facility":28,"status":11,"city":29,"state":11,"zip":11,"country":30,"countryCode":11,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Başakşehir Çam and Sakura City Hospital","Istanbul","Turkey (Türkiye)",{"type":32,"coordinates":33},"Point",[34,35],28.94966,41.01384,{"lat":35,"lon":34},[38],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"type":40,"investigatorFullName":22,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Medical Doctor",[43,45,48,50],{"name":44,"class":6},"Umraniye Education and Research Hospital",{"name":46,"class":47},"Gaziantep City Hospital","OTHER",{"name":49,"class":47},"Namik Kemal University School of Medicine, Tekirdag",{"name":51,"class":52},"Bakırçay University, Faculty of Medicine","UNKNOWN","100606020","predictors-of-gon-blockade-success-in-migraine-100606020",false,"NCT07170111","Predictors of GON Blockade Success in Migraine","Predictive Factors for the Success of Greater Occipital Nerve Block in Migraine: A Multicenter Prospective Study","Inclusion Criteria:\n\n* Diagnosis of migraine for at least 6 months, according to ICHD-3 criteria\n* Age between 18 and 65 years\n* Inadequate response to preventive therapy used regularly for at least 3 months\n* Planned treatment with greater occipital nerve block (GONB) and provision of signed informed consent\n* Receiving GONB treatment for the first time\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Presence of malignancy\n* Coagulopathy or anticoagulant therapy\n* Local infection, open wound, or history of surgery at the injection site preventing the procedure\n* History of severe neurological or psychiatric disorders\n* Receipt of interventional treatment (e.g., Botox, acupuncture, neural therapy, nerve blocks) within the last 3 months\n* Use of steroids or immunosuppressive therapy\n* Start of a new preventive therapy within the last 3 months\n* Inability to comply with keeping a headache diary\n* Known hypersensitivity or allergy to bupivacaine","ALL","18 Years","65 Years",{"count":64,"type":65},460,"ESTIMATED","INTERVENTIONAL",[68],"NA","This multicenter, prospective cohort study aims to identify clinical and demographic predictors that influence the success of greater occipital nerve (GON) block in patients with migraine.\n\nPatients will be evaluated at baseline, on each injection day, and at one- and three-month follow-ups. Study parameters include demographics, migraine type and duration, comorbidities, headache characteristics, treatment history, and validated outcome measures such as the Numeric Rating Scale (NRS), Headache Impact Test-6 (HIT-6), and Global Rating of Change (GRoC).\n\nThe goal is to establish predictive factors of treatment success in order to optimize patient selection and contribute robust multicenter evidence to individualized migraine management",[71],"Migraine",[73,74,75,76,77],"migraine","GON block","greater occipital nerve","greater occipital nerve block","predictive factors","NOT_YET_RECRUITING","2025-09-05",{"date":81,"type":82},"2025-09-12","ACTUAL",{"date":84,"type":65},"2025-09-15",{"date":86,"type":65},"2026-12-01",{"name":5,"class":6},1]